Abstract
This review presents the clinical pharmacokinetics of bortezomib. Aspects regarding metabolism, pharmacodynamics and drug interactions are also discussed.
Footnotes
- Received December 18, 2006.
- Revision received January 22, 2007.
- Accepted January 23, 2007.
- Copyright © 2007 The Author(s). Published by the International Institute of Anticancer Research.
In this issue
Jump to section
Related Articles
Cited By...
- In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline
- Drug interaction between bortezomib and tuberculosis treatment: a case report
- Proteasome Inhibition Increases Recruitment of I{kappa}B Kinase {beta} (IKK{beta}), S536P-p65, and Transcription Factor EGR1 to Interleukin-8 (IL-8) Promoter, Resulting in Increased IL-8 Production in Ovarian Cancer Cells
- Proteasome Inhibition by Bortezomib Increases IL-8 Expression in Androgen-Independent Prostate Cancer Cells: The Role of IKK{alpha}
- Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells
- Potential Pharmacokinetic Interactions Affecting Antitumor Drug Disposition in Cancer Patients